Spots Global Cancer Trial Database for PD-1 Inhibitor and Nab-paclitaxel and Bevacizumab in CUP

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: PD-1 Inhibitor and Nab-paclitaxel and Bevacizumab in CUP

Official Title: Phase 2, Open-label, Single Center, Prospective Study of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Combined With Nab-paclitaxel and Bevacizumab in the Second-line Treatment of Patients With Cancer of Unknown Primary (CUP)

Study ID: NCT04848597

Conditions

Cancer of Unknown Primary

Interventions

Recombinant humanized anti-PD-1 monoclonal antibody injection

Study Description

Brief Summary: This trial is a single-center, prospective, single-arm Phase II clinical study. The purpose is to evaluate the efficacy and safety of recombinant humanized anti-PD-1 monoclonal antibody combined with albumin paclitaxel and bevacizumab in the second-line treatment of patients with unknown primary tumors.

Detailed Description: Recombinant humanized anti-PD-1 monoclonal antibody combined with albumin paclitaxel and bevacizumab treatment, once every 3 weeks, treatment until disease progression, intolerable adverse reactions, patient death or withdrawal informed agree.After treatment, the patients was followed up every 9 weeks for follow-up treatment and survival.